A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations

NCT05420779 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer Metastatic

Interventions

DRUG: TSL-1502 capsules(low dose)
DRUG: TSL-1502 capsules(high dose)
DRUG: Investigator's choice of chemotherapy

Sponsor

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.